Delcath Systems/$DCTH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Delcath Systems
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
- Ticker
- $DCTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 156
- Headquarters
- Queensbury, United States
- Website
- www.delcath.com
Delcath Systems Metrics
BasicAdvanced
$503M
985.71
$0.01
0.57
-
Price and volume
Market cap
$503M
Beta
0.57
52-week high
$17.42
52-week low
$8.12
Average daily volume
321K
Financial strength
Current ratio
9.83
Quick ratio
8.423
Long term debt to equity
0.019
Total debt to equity
0.02
Profitability
EBITDA (TTM)
-1.455
Gross margin (TTM)
87.05%
Net profit margin (TTM)
0.56%
Operating margin (TTM)
-1.90%
Effective tax rate (TTM)
58.82%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
-0.89%
Return on equity (TTM)
0.47%
Valuation
Price to earnings (TTM)
985.714
Price to revenue (TTM)
5.496
Price to book
4.14
Price to tangible book (TTM)
4.14
Price to free cash flow (TTM)
29.954
Free cash flow yield (TTM)
3.34%
Free cash flow per share (TTM)
0.484
Growth
Revenue change (TTM)
35.85%
Earnings per share change (TTM)
-71.87%
3-year revenue growth (CAGR)
230.76%
10-year revenue growth (CAGR)
49.45%
3-year earnings per share growth (CAGR)
-83.22%
What the Analysts think about Delcath Systems
Analyst ratings (Buy, Hold, Sell) for Delcath Systems stock.
Analyst projections of the future price of Delcath Systems stock.
Bulls say / Bears say
Second-quarter revenue rose to $29.1 million from $24.2 million a year earlier, with HEPZATO procedure volume up about 30%. Delcath lifted its 2026 revenue outlook to $104–108 million and had 31 active treatment centres. (Delcath Systems)
The business is already profitable and has substantial funding to support its expansion: Delcath reported $2.7 million of second-quarter net income, a 90% gross margin and $95.9 million in cash and investments, with no debt. (SEC)
Recent independent data from a 12-patient liver-dominant uveal melanoma cohort reported a 66.7% response rate and median hepatic progression-free survival of 18.4 months. If further evidence confirms these results, it could support confidence in the treatment and wider adoption. (Delcath Systems)
Sales depend heavily on one product: HEPZATO generated $27.1 million of the $29.1 million in second-quarter revenue, and its US approval covers a defined group of patients with metastatic uveal melanoma. This concentration makes growth vulnerable to any slowdown in use of that treatment. (Delcath Systems, SEC)
Higher research and commercial spending is weakening operating leverage: first-half operating income fell to $0.8 million from $3.2 million even as revenue grew. Second-quarter adjusted EBITDA also declined to $7.6 million from $9.8 million year on year. (SEC, Delcath Systems)
The case for expanding into other cancers rests on early evidence: a retrospective breast-cancer study included just 15 patients, and 80% had grade 3–4 post-procedure adverse events. That small study leaves both the benefit and tolerability of treatment in this new group uncertain. (Delcath Systems)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
Delcath Systems Financial Performance
Revenues and expenses
Delcath Systems Earnings Performance
Company profitability
Upcoming events
No upcoming events
Delcath Systems News
AllArticlesVideos
Funds containing Delcath Systems
Fund name | Fund size | $DCTH weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.